InvestorsHub Logo
Followers 32
Posts 2552
Boards Moderated 0
Alias Born 07/16/2006

Re: gfp927z post# 37834

Wednesday, 10/26/2011 5:56:59 PM

Wednesday, October 26, 2011 5:56:59 PM

Post# of 51847
OK, maybe this angle will clarify it better than my first two posts did: Pharmas partner by geography all the time. If you have rights in the US, you have it for whatever indications you choose to pursue. CX-516 was sliced up by indication, with Servier having worldwide control over neurodegeneration. A company partnering with Cortex in North America could only develop CX-516 for indications other than Alzheimer's, Parkinson's, Huntington's, and could have been faced with another company trying to sell the same drug in the same territory, but possibly for a different price. That is not what this current scenario would produce.

NeuroInvestment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News